Maternal and paternal history of atopic disease confers an equal — and greater — risk for atopic dermatitis in offspring and increases if both parents have a history of 1 or more atopic diseases.
Current guidelines for the treatment of atopic dermatitis can help to inform decision-making in clinical practice.
An emerging paradigm in itch biology is supported by findings that suggest KLK7 as an influence in the disease pathogenesis of atopic dermatitis.
PROMIS SD and SRI 8-item bank short forms demonstrate sufficient validity and feasibility to be used as assessment tools for burden of sleep in adults with atopic dermatitis.
Maternal depression in the postpartum period and beyond is associated with higher odds of atopic dermatitis for the child throughout childhood and adolescence.
Positive topline data were announced from the pivotal phase 3 TRuE-AD2 study of ruxolitinib cream for the treatment of atopic dermatitis in patients aged ≥12 years.
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
The new Patient-Reported Outcomes Measurement Information System (PROMIS) Itch Questionnaire (PIQ) short forms may have application in clinical trial and practice.
Results showed that the 4mg dose of baricitinib plus TCS met the primary end point, with 31.5% of patients achieving EASI75 compared with 17.2% of patients in the placebo plus TCS group (P ≤.05).
Tretinoin 0.05% lotion was significantly more effective than vehicle in reducing inflammatory and noninflammatory lesions in women with moderate acne, with notable improvements in treating women with severe acne.